FdaApplication
NDA 021462
Identifiers
- fda_app_no: NDA021462
Properties
| Property | Value |
|---|---|
| applicant_name | ELI LILLY AND CO |
| application_type | NDA |
| approval_date | 2004-02-04 |
Revenue by product
ALIMTA
| Period | Revenue |
|---|---|
| Q4 2023 | $44.9M |
| Q3 2023 | $53.5M |
| Q4 2022 | $236.6M |
| Q3 2022 | $119.4M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ALIMTA | PEMETREXED DISODIUM | EQ 100MG BASE/VIAL | POWDER;INTRAVENOUS |
| ALIMTA | PEMETREXED DISODIUM | EQ 500MG BASE/VIAL | POWDER;INTRAVENOUS |
2 products